Entero Healthcare Solutions Limited has announced the successful closing of its acquisition of a 51.5% stake in Anand Chemiceutics Private Limited, a distributor of diagnostic products and a partner for global diagnostic and MedTech companies. This strategic move aims to scale Entero's presence in the large and high-growth MedTech market, leveraging the combined distribution strength, geographical reach, and expertise of both companies. Anand Chemiceutics, established in 2003 and headquartered in Pune, brings over two decades of experience, a strong pan-India network of over 1,500 laboratories, hospitals, and government institutions, and specialized capabilities in distributing diagnostic equipment, reagents, and providing turnkey solutions. The acquisition is expected to accelerate Entero's vision of becoming an integrated and comprehensive healthcare supply chain solutions provider. Mr. Prabhat Agrawal, MD and CEO of Entero Healthcare, welcomed Anand Chemiceutics, highlighting the strategic positioning for scale in the attractive MedTech segment due to their track record and global partnerships. Mr. Jayesh Sancheti, MD of Anand Chemiceutics, expressed enthusiasm for integrating Anand Chemiceutics' legacy with Entero's scale and technology to create a powerhouse in patient lifecycle impact. Entero Healthcare had initially announced this acquisition on November 12, 2025. The MedTech segment is projected to contribute over ₹1,000 crore in annualized revenue in the next financial year.
